Edwards Lifesciences Corporation $EW Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 8.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 19,010,227 shares of the medical research company’s stock after purchasing an additional 1,423,365 shares during the quarter. Bank of New York Mellon Corp’s holdings in Edwards Lifesciences were worth $1,478,425,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in EW. Norges Bank acquired a new stake in Edwards Lifesciences in the second quarter worth $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of Edwards Lifesciences by 111.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after acquiring an additional 4,805,819 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Edwards Lifesciences by 127.5% in the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after acquiring an additional 3,864,908 shares during the period. Jennison Associates LLC lifted its position in Edwards Lifesciences by 19.6% in the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after purchasing an additional 2,287,783 shares during the last quarter. Finally, Holocene Advisors LP boosted its stake in Edwards Lifesciences by 35.2% during the 2nd quarter. Holocene Advisors LP now owns 4,703,977 shares of the medical research company’s stock valued at $367,898,000 after purchasing an additional 1,223,460 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.8%

Shares of EW stock opened at $83.59 on Wednesday. The stock has a 50-day simple moving average of $84.97 and a 200 day simple moving average of $80.93. The stock has a market capitalization of $48.51 billion, a P/E ratio of 36.03, a P/E/G ratio of 3.22 and a beta of 0.95. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the company earned $0.67 EPS. Edwards Lifesciences’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on EW shares. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 12th. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Evercore ISI reiterated an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research report on Monday, January 5th. BTIG Research reissued a “buy” rating and issued a $103.00 price target (up previously from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. Finally, Piper Sandler restated an “overweight” rating and set a $98.00 price objective (up from $95.00) on shares of Edwards Lifesciences in a research note on Tuesday, January 20th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $96.82.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total value of $971,384.40. Following the sale, the vice president owned 31,870 shares of the company’s stock, valued at $2,729,984.20. This trade represents a 26.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 57,824 shares of company stock worth $4,863,323. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.